The global “Vasopressin For Vasoplegic Shock Market”, size is expected to gain momentum by reaching USD 2,657.9 million by 2027, while exhibiting a stellar CAGR of 14.8% between 2020 and 2027. This is attributable to the increasing prevalence of cardiovascular surgeries that propels the demand for vasopressin for vasoplegic shock across the globe. This information is published by Fortune Business Insights, in its latest report, titled, “Vasopressin for Vasoplegic Shock Market Size, Share & COVID-19 Impact Analysis, By Application (Sepsis, Post Cardiac Surgery, and Others) Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 890.9 million in 2019.
Get Request a Sample Copy of the Vasopressin for Vasoplegic Shock Report:
Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.
Major Vasopressin for Vasoplegic Shock Market Key players covered in the report include:
- Endo International plc (Dublin, Ireland)
- AMOMED Pharma (Vienna, Austria)
- La Jolla Pharmaceutical Company (California, U.S.)
- Pfizer Inc. (New York, U.S.)
- Ferring Vasopressin for Vasoplegic Shock (Saint-Prex, Switzerland)
- Fresenius Kabi Canada (Toronto, Canada)
- Astellas Pharma (Tokyo, Japan)
- Eagle Vasopressin for Vasoplegic Shock, Inc. (New Jersey, U.S.)
Vasopressin for Vasoplegic Shock Market Analysis 2021:
Increasing Incidence of Cardiovascular Surgeries to Augment Growth
According to the Centers for Disease Control and Prevention (CDC), every year about 340,000 Coronary Artery Bypass Grafting (CABG) procedures are performed in the U.S. The increasing number of cardiovascular surgeries propels the demand for vasopressin to control the blood flow. Additionally, the growing number of CABG procedures and sepsis patients are boosting the demand for innovative vasopressin treatment options. This is expected to bode well for the global vasopressin for vasoplegic shock market growth during the forecast period.
Increasing Prevalence of Sepsis in North America to Favor Growth
Among all the regions, North America stood at USD 561.3 million in 2019 and is expected to hold the highest position in the global market in the forthcoming years. This is ascribable to the increasing prevalence of sepsis that drives the demand for advanced vasopressin for vasoplegic shock treatment procedures in the region.
The market in Europe is expected to experience a significant growth backed by surging investments in R&D by the government as well as major companies to develop advanced vasopressin for vasoplegic shock treatment between 2020 and 2027.
Prominent Companies Focus on Investment in R&D Activities to Develop Innovative Vasopressin for Vasoplegic Shock
The global vasopressin for vasoplegic shock market is fragmented by the presence of key players that are focusing on raising investments to develop advanced vasopressin for vasoplegic shock treatment. Additionally, the major companies are striving to maintain their presence in the global marketplace by adopting strategies such as partnership, collaboration, and merger and acquisition to gain a competitive edge over their rivals during the forecast period.
- April 2018 – Eagle Vasopressin for Vasoplegic Shock, Inc announced the approval of its new drug application, ANDA for 1ml vasopressin injection. The product is a original generic version of Endo International plc’s Vasostrict formulation.
Have Any Query? Ask Our Experts:
Table of Content:
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
4.1. Recent Industry Developments Such as Mergers & Acquisitions
4.2. Regulatory Scenario for Key Countries
4.3. New Product Launch
4.4. Statistics on Prevalence of Cardiac Disorders for Key Countries/Regions
4.5. Pipeline Analysis
- Global Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Application
5.2.2. Post Cardiac Surgery
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
- North America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Application
6.2.2. Post Cardiac Surgery
6.3. Market Analysis, Insights and Forecast – By Country
- Europe Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Application
7.2.2. Post Cardiac Surgery
7.3. Market Analysis, Insights and Forecast – By Country/Sub Region
7.3.7. Rest of Europe
- Asia Pacific Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Application
8.2.2. Post Cardiac Surgery
8.3. Market Analysis, Insights and Forecast – By Country/Sub Region
8.3.5. Southeast Asia
8.3.6. Rest of Asia Pacific
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune -411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Related Reports :